Epworth Healthcare

Richmond, Victoria 3122

5 studies enrolling now · 27 studies all time

What they study most

Adenocarcinoma of the Lung, Advanced Solid Tumors, Angioimmunoblastic T-cell Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma, Bladder Cancer, Breast Cancer, Breast Neoplasms, Colorectal Cancer, Follicular T-Cell Lymphoma, Gastric Adenocarcinoma, Genetic Predisposition

Studies at this site

• A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — Recruiting now
• Pancreatic Cancer Early Detection Consortium — Recruiting now
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — Recruiting now
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma — Recruiting now
• APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies — Recruiting now
• A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma — Running, not enrolling
• A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment — Running, not enrolling
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Running, not enrolling
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) — Status unconfirmed
• SI Joint Stabilization in Long Fusion to the Pelvis — Completed
• Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM — Running, not enrolling
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) — Completed
• A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors — Completed
• CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) — Completed
• Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors — Stopped early
• Dysport® Adult Lower Limb Spasticity Study — Completed
• Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors — Completed
• NLA101 in Adults Receiving High Dose Chemotherapy for AML — Stopped early
• A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung — Completed
• Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole — Completed
• Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma — Completed
• Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas — Stopped early
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed
• Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma — Completed
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer — Completed
• Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer — Completed